,address1,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,earningsQuarterlyGrowth,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,earningsGrowth,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Darwinweg 24,Leiden,2333 CR,Netherlands,31 71 524 7400,31 71 524 7445,https://www.pharming.com,Biotechnology,Healthcare,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",332,"{'maxAge': 1, 'name': 'Dr. Sijmen  de Vries M.B.A., M.D., MBA', 'age': 63, 'title': 'Pres, CEO & Exec. Director', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 1176000, 'exercisedValue': 0, 'unexercisedValue': 0}",7,1,8,4,4,1693526400,1672444800,86400,4,1.22,1.25,1.244,1.3,1.22,1.25,1.244,1.3,0.0,0.858858,64.15,24881291,24881291,5034509,6536134,6536134,0.0,0.0,0,0,845725376,0.8945,1.419,4.0995526,1.1407,1.126925,0.0,0.0,EUR,823486912,-0.07958,615402389,659177984,0.023,0.21089001,0.304,4.2203946,1672444800,1703980800,1688083200,-0.916,-16418000,-0.02,0.02,1:10,1362441600,3.992,-38.459,AMS,EQUITY,PHARM.AS,PHARM.AS,PHARMING GROUP,Pharming Group N.V.,929516400,Europe/Amsterdam,CEST,7200000,1.283,33.84,1.11,7.08,1.92,1.9,buy,6,192372992,0.292,-21412000,170134000,3.472,4.289,206296992,84.909,0.318,-0.040999997,-0.08208,188060000,11832875,-14555000,-0.928,0.095,0.91054,-0.10379,-0.13095,USD,
1,Darwinweg 24,Leiden,2333 CR,Netherlands,31 71 524 7400,31 71 524 7445,https://www.pharming.com,Biotechnology,Healthcare,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",332,"{'maxAge': 1, 'name': 'Mr. Jeroen  Wakkerman', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1969, 'exercisedValue': 0, 'unexercisedValue': 0}",7,1,8,4,4,1693526400,1672444800,86400,4,1.22,1.25,1.244,1.3,1.22,1.25,1.244,1.3,0.0,0.858858,64.15,24881291,24881291,5034509,6536134,6536134,0.0,0.0,0,0,845725376,0.8945,1.419,4.0995526,1.1407,1.126925,0.0,0.0,EUR,823486912,-0.07958,615402389,659177984,0.023,0.21089001,0.304,4.2203946,1672444800,1703980800,1688083200,-0.916,-16418000,-0.02,0.02,1:10,1362441600,3.992,-38.459,AMS,EQUITY,PHARM.AS,PHARM.AS,PHARMING GROUP,Pharming Group N.V.,929516400,Europe/Amsterdam,CEST,7200000,1.283,33.84,1.11,7.08,1.92,1.9,buy,6,192372992,0.292,-21412000,170134000,3.472,4.289,206296992,84.909,0.318,-0.040999997,-0.08208,188060000,11832875,-14555000,-0.928,0.095,0.91054,-0.10379,-0.13095,USD,
2,Darwinweg 24,Leiden,2333 CR,Netherlands,31 71 524 7400,31 71 524 7445,https://www.pharming.com,Biotechnology,Healthcare,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",332,"{'maxAge': 1, 'name': 'Ms. Mireille  Sanders M.Sc.', 'age': 54, 'title': 'Chief Operations Officer', 'yearBorn': 1968, 'exercisedValue': 0, 'unexercisedValue': 0}",7,1,8,4,4,1693526400,1672444800,86400,4,1.22,1.25,1.244,1.3,1.22,1.25,1.244,1.3,0.0,0.858858,64.15,24881291,24881291,5034509,6536134,6536134,0.0,0.0,0,0,845725376,0.8945,1.419,4.0995526,1.1407,1.126925,0.0,0.0,EUR,823486912,-0.07958,615402389,659177984,0.023,0.21089001,0.304,4.2203946,1672444800,1703980800,1688083200,-0.916,-16418000,-0.02,0.02,1:10,1362441600,3.992,-38.459,AMS,EQUITY,PHARM.AS,PHARM.AS,PHARMING GROUP,Pharming Group N.V.,929516400,Europe/Amsterdam,CEST,7200000,1.283,33.84,1.11,7.08,1.92,1.9,buy,6,192372992,0.292,-21412000,170134000,3.472,4.289,206296992,84.909,0.318,-0.040999997,-0.08208,188060000,11832875,-14555000,-0.928,0.095,0.91054,-0.10379,-0.13095,USD,
3,Darwinweg 24,Leiden,2333 CR,Netherlands,31 71 524 7400,31 71 524 7445,https://www.pharming.com,Biotechnology,Healthcare,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",332,"{'maxAge': 1, 'name': 'Susanne  Embleton', 'title': 'Investor Relations Mang.', 'exercisedValue': 0, 'unexercisedValue': 0}",7,1,8,4,4,1693526400,1672444800,86400,4,1.22,1.25,1.244,1.3,1.22,1.25,1.244,1.3,0.0,0.858858,64.15,24881291,24881291,5034509,6536134,6536134,0.0,0.0,0,0,845725376,0.8945,1.419,4.0995526,1.1407,1.126925,0.0,0.0,EUR,823486912,-0.07958,615402389,659177984,0.023,0.21089001,0.304,4.2203946,1672444800,1703980800,1688083200,-0.916,-16418000,-0.02,0.02,1:10,1362441600,3.992,-38.459,AMS,EQUITY,PHARM.AS,PHARM.AS,PHARMING GROUP,Pharming Group N.V.,929516400,Europe/Amsterdam,CEST,7200000,1.283,33.84,1.11,7.08,1.92,1.9,buy,6,192372992,0.292,-21412000,170134000,3.472,4.289,206296992,84.909,0.318,-0.040999997,-0.08208,188060000,11832875,-14555000,-0.928,0.095,0.91054,-0.10379,-0.13095,USD,
4,Darwinweg 24,Leiden,2333 CR,Netherlands,31 71 524 7400,31 71 524 7445,https://www.pharming.com,Biotechnology,Healthcare,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",332,"{'maxAge': 1, 'name': 'Mr. Ruud  Van Outersterp', 'age': 58, 'title': 'Chief Ethics & Compliance Officer', 'yearBorn': 1964, 'exercisedValue': 0, 'unexercisedValue': 0}",7,1,8,4,4,1693526400,1672444800,86400,4,1.22,1.25,1.244,1.3,1.22,1.25,1.244,1.3,0.0,0.858858,64.15,24881291,24881291,5034509,6536134,6536134,0.0,0.0,0,0,845725376,0.8945,1.419,4.0995526,1.1407,1.126925,0.0,0.0,EUR,823486912,-0.07958,615402389,659177984,0.023,0.21089001,0.304,4.2203946,1672444800,1703980800,1688083200,-0.916,-16418000,-0.02,0.02,1:10,1362441600,3.992,-38.459,AMS,EQUITY,PHARM.AS,PHARM.AS,PHARMING GROUP,Pharming Group N.V.,929516400,Europe/Amsterdam,CEST,7200000,1.283,33.84,1.11,7.08,1.92,1.9,buy,6,192372992,0.292,-21412000,170134000,3.472,4.289,206296992,84.909,0.318,-0.040999997,-0.08208,188060000,11832875,-14555000,-0.928,0.095,0.91054,-0.10379,-0.13095,USD,
5,Darwinweg 24,Leiden,2333 CR,Netherlands,31 71 524 7400,31 71 524 7445,https://www.pharming.com,Biotechnology,Healthcare,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",332,"{'maxAge': 1, 'name': 'Dr. Anurag  Relan M.D., MPH', 'age': 50, 'title': 'Chief Medical Officer', 'yearBorn': 1972, 'exercisedValue': 0, 'unexercisedValue': 0}",7,1,8,4,4,1693526400,1672444800,86400,4,1.22,1.25,1.244,1.3,1.22,1.25,1.244,1.3,0.0,0.858858,64.15,24881291,24881291,5034509,6536134,6536134,0.0,0.0,0,0,845725376,0.8945,1.419,4.0995526,1.1407,1.126925,0.0,0.0,EUR,823486912,-0.07958,615402389,659177984,0.023,0.21089001,0.304,4.2203946,1672444800,1703980800,1688083200,-0.916,-16418000,-0.02,0.02,1:10,1362441600,3.992,-38.459,AMS,EQUITY,PHARM.AS,PHARM.AS,PHARMING GROUP,Pharming Group N.V.,929516400,Europe/Amsterdam,CEST,7200000,1.283,33.84,1.11,7.08,1.92,1.9,buy,6,192372992,0.292,-21412000,170134000,3.472,4.289,206296992,84.909,0.318,-0.040999997,-0.08208,188060000,11832875,-14555000,-0.928,0.095,0.91054,-0.10379,-0.13095,USD,
6,Darwinweg 24,Leiden,2333 CR,Netherlands,31 71 524 7400,31 71 524 7445,https://www.pharming.com,Biotechnology,Healthcare,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",332,"{'maxAge': 1, 'name': 'Mr. Stephen  Toor', 'age': 51, 'title': 'Chief Commercial Officer & GM Americas', 'yearBorn': 1971, 'exercisedValue': 0, 'unexercisedValue': 0}",7,1,8,4,4,1693526400,1672444800,86400,4,1.22,1.25,1.244,1.3,1.22,1.25,1.244,1.3,0.0,0.858858,64.15,24881291,24881291,5034509,6536134,6536134,0.0,0.0,0,0,845725376,0.8945,1.419,4.0995526,1.1407,1.126925,0.0,0.0,EUR,823486912,-0.07958,615402389,659177984,0.023,0.21089001,0.304,4.2203946,1672444800,1703980800,1688083200,-0.916,-16418000,-0.02,0.02,1:10,1362441600,3.992,-38.459,AMS,EQUITY,PHARM.AS,PHARM.AS,PHARMING GROUP,Pharming Group N.V.,929516400,Europe/Amsterdam,CEST,7200000,1.283,33.84,1.11,7.08,1.92,1.9,buy,6,192372992,0.292,-21412000,170134000,3.472,4.289,206296992,84.909,0.318,-0.040999997,-0.08208,188060000,11832875,-14555000,-0.928,0.095,0.91054,-0.10379,-0.13095,USD,
7,Darwinweg 24,Leiden,2333 CR,Netherlands,31 71 524 7400,31 71 524 7445,https://www.pharming.com,Biotechnology,Healthcare,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",332,"{'maxAge': 1, 'name': 'Dr. Alexander  Breidenbach M.B.A.', 'title': 'Chief Bus. Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",7,1,8,4,4,1693526400,1672444800,86400,4,1.22,1.25,1.244,1.3,1.22,1.25,1.244,1.3,0.0,0.858858,64.15,24881291,24881291,5034509,6536134,6536134,0.0,0.0,0,0,845725376,0.8945,1.419,4.0995526,1.1407,1.126925,0.0,0.0,EUR,823486912,-0.07958,615402389,659177984,0.023,0.21089001,0.304,4.2203946,1672444800,1703980800,1688083200,-0.916,-16418000,-0.02,0.02,1:10,1362441600,3.992,-38.459,AMS,EQUITY,PHARM.AS,PHARM.AS,PHARMING GROUP,Pharming Group N.V.,929516400,Europe/Amsterdam,CEST,7200000,1.283,33.84,1.11,7.08,1.92,1.9,buy,6,192372992,0.292,-21412000,170134000,3.472,4.289,206296992,84.909,0.318,-0.040999997,-0.08208,188060000,11832875,-14555000,-0.928,0.095,0.91054,-0.10379,-0.13095,USD,
8,Darwinweg 24,Leiden,2333 CR,Netherlands,31 71 524 7400,31 71 524 7445,https://www.pharming.com,Biotechnology,Healthcare,"Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.",332,"{'maxAge': 1, 'name': 'Dr. Bruno M. L. Giannetti', 'age': 70, 'title': 'Consultant', 'yearBorn': 1952, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",7,1,8,4,4,1693526400,1672444800,86400,4,1.22,1.25,1.244,1.3,1.22,1.25,1.244,1.3,0.0,0.858858,64.15,24881291,24881291,5034509,6536134,6536134,0.0,0.0,0,0,845725376,0.8945,1.419,4.0995526,1.1407,1.126925,0.0,0.0,EUR,823486912,-0.07958,615402389,659177984,0.023,0.21089001,0.304,4.2203946,1672444800,1703980800,1688083200,-0.916,-16418000,-0.02,0.02,1:10,1362441600,3.992,-38.459,AMS,EQUITY,PHARM.AS,PHARM.AS,PHARMING GROUP,Pharming Group N.V.,929516400,Europe/Amsterdam,CEST,7200000,1.283,33.84,1.11,7.08,1.92,1.9,buy,6,192372992,0.292,-21412000,170134000,3.472,4.289,206296992,84.909,0.318,-0.040999997,-0.08208,188060000,11832875,-14555000,-0.928,0.095,0.91054,-0.10379,-0.13095,USD,
